Development and validation of a prediction model for serious infections in rheumatoid arthritis patients treated with tocilizumab in Japan.

ABSTRACT:

Objectives

To develop a prediction model for serious infections (SIs) in rheumatoid arthritis (RA) patients treated with tocilizumab in Japan and to evaluate the model's performance compared to previously developed models, i.e., 'DANBIO' and 'postmarketing surveillance' (PMS).

Method

This non-interventional retrospective cohort study utilized the Medical Data Vision database in Japan. The study population was derived from patients ≥ 18 years with RA who initiated tocilizumab between April 2008 and July 2021. SIs were assessed during the 1-year follow-up from tocilizumab initiation. The candidate predictors were identified based on previous studies, known risk factors, potentially relevant factors, and data availability. The prediction model was developed using logistic regre

SUBMITTER: Nanki T 

PROVIDER: S-EPMC11865113 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature